Sinar Daily on MSN2h
Seven-year trial shows 48 per cent survival with dual immunotherapyPatients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback